In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets

In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets

Preclinical molecular models are useful that mimic a patient´s response to targeted therapy. Here, the authors establish an in vivo inducible RNAi-mediated gene silencing system in patient-derived xenograft models of acute leukemia to identify individual vulnerabilities and therapeutic targets.

Guardado en:
Detalles Bibliográficos
Autores principales: Michela Carlet, Kerstin Völse, Jenny Vergalli, Martin Becker, Tobias Herold, Anja Arner, Daniela Senft, Vindi Jurinovic, Wen-Hsin Liu, Yuqiao Gao, Veronika Dill, Boris Fehse, Claudia D. Baldus, Lorenz Bastian, Lennart Lenk, Denis M. Schewe, Johannes W. Bagnoli, Binje Vick, Jan Philipp Schmid, Alexander Wilhelm, Rolf Marschalek, Philipp J. Jost, Cornelius Miething, Kristoffer Riecken, Marc Schmidt-Supprian, Vera Binder, Irmela Jeremias
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/6e797a213a574904a9cff02ded829844
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares